2009年，英派药业选择投身“合成致死”这一前沿领域时，全球范围内尚无PARP抑制剂获批。彼时，这一方向的前景并不明朗，可谓风险重重。然而，英派选择了以十余年的持续攻坚，回应这份不确定的挑战。
2025年1月，英派药业自主研发的核心产品PARP抑制剂塞纳帕利（商品名：派舒宁®）在中国获批上市，同年纳入国家医保目录，并已向欧洲药品管理局递交上市申请。2026年5月13日，公司成功登陆港交所。今年7月底，英派药业与全球专科制药公司Pharmanovia达成独家合作，授予后者在欧洲、中东、北非、澳大利亚及新西兰地区对塞纳帕利（用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌维持单药治疗）的独家生产、研发及商业化权利，是塞纳帕利走向全球市场的重要一步。从2009到2026，十七年光阴，这家公司完成了从早期研发到商业化、再走向资本市场的阶段性跨越。
“上市只是公司发展新阶段的起点。我们最终的目标，是把更多差异化的新药、好药带给全球实体瘤患者。”英派药业首席执行官（CEO）蔡遂雄博士近期在接受药明康德采访时如是说。蔡遂雄博士在英派药业创立之初便加入，一路见证了公司从零起步、一路跋涉的峥嵘岁月。
在他看来，支撑公司跨越漫长周期的，既源于团队对科学方向的坚定信仰，也离不开产业生态圈的协作支持。他在采访中特别提到投资者的全程信任，CRDMO合作伙伴药明康德的一路陪伴，以及众多合作伙伴的紧密协作。“在创新药研发的漫长之路上，没有任何一家企业可以包打天下。开放共赢的生态合作，并非锦上添花，而是实现创新药成果落地的必经之路。”蔡遂雄博士说。
十七年砥砺前行，英派药业不仅走通了从实验室到惠及病患的完整新药研发路径，也在一次次突破中，为其下一程创新积蓄了更多底气和力量。
以下，是我们与英派药业CEO蔡遂雄博士的一次对话。
药明康德：祝贺英派近期成功IPO。您一路参与了公司的发展历程，能否分享下您对这一阶段的个人体会？
蔡遂雄博士：英派药业于今年5月13日在港交所主板挂牌，这对公司和行业而言都是里程碑时刻。我很荣幸完整见证了英派从2009年创立至今17年的坚守历程，感慨颇深。当年我们设定公司整体策略为立足中国，放眼世界，做best-in-class（BIC）新药，锚定“合成致死”这一方向时，全球还尚无PARP抑制剂获批，这一领域的临床路径和商业化前景均充满未知。十余年持续攻坚，我们不仅成功研发出核心产品塞纳帕利并实现商业化上市，还在此基础上搭建起更为系统、全面的“合成致死”管线。
同时，我们并未止步于此。面向更广阔的治疗需求，我们主动拓展创新边界，自研搭建了双载荷抗体偶联药物（ADC）平台及蛋白降解靶向嵌合体（PROTAC）两大前沿技术平台。上市是英派迈向新发展阶段的起点。我们的最终目标，是持续将更多差异化新药、好药，带给全球实体瘤患者。
药明康德：塞纳帕利已经在中国获批，且目前已在欧洲申报上市。回顾这款新药研发历程，您有哪些体会？例如过程中遇到了哪些挑战？您从中获得了哪些思考？
蔡遂雄博士：塞纳帕利是英派自主研发的核心PARP抑制剂产品。2012年确定候选化合物，2025年在中国获批上市，同年即被纳入国家医保目录，为卵巢癌患者带来了切实可及的新治疗选择。同年，欧洲药品管理局也已受理其上市许可申请，在不久的将来有望造福更多病患。近期我们与Pharmanovia的合作，是公司将已验证的治疗方案带给全球更多患者的重要一步，预计塞纳帕利在获批后将更快地触达合作区域内的目标患者，助力提供高质量治疗方案，满足未被满足的临床需求。
回望研发之路，我们主要克服了两大挑战：其一，是战略定力与资源约束的博弈。彼时PARP领域前景尚不明朗，公司早期研发资源及团队规模极为有限。英派能够从实验室走到产品商业化、登陆资本市场，离不开始终坚守一线的核心研发团队，坚持用BIC标准研究和开发新药，以及长期信任支持我们的投资人。正是这份“在不确定性中坚持确定性”的信念，支撑我们走过了漫长岁月。其二，是临床开发路径上的关键战略抉择。2019年，我们凭借对合成致死机制的深刻理解与扎实的1期数据，得以跳过2期，直接启动3期FLAMES研究，将研发周期压缩两年以上。更关键的是，我们选择了一条更具挑战但更可能具临床价值的路径——不局限BRCA/HRR突变的全人群一线方案，最终凭借完整循证数据，拿下卵巢癌全人群一线维持治疗的适应症。
图片来源：123RF
这段研发历程也让我们深刻体会到：科学的战略取舍，比单纯加大投入更具决定性。在资源有限的前提下，基于临床数据的精准判断与果断决策，往往是突破瓶颈的关键。此外，新药研发从来不是一家企业的孤军奋战。单一企业很难独立走完新药研发全链条，产业协同与开放合作是降低风险、提速进程的重要杠杆。塞纳帕利在整个研究、开发及生产的过程中，药明康德的平台能力帮助我们大幅缩短周期、降低试错成本，这也是双方合作加速创新的缩影。
药明康德：除了塞纳帕利，英派药业在“合成致死”领域还有多条管线在推进。能否分享下公司在管线布局、靶点选择方面的考量？
蔡遂雄博士：我们的管线布局，是基于“产品迭代+协同规划+前沿机制探索”的系统性思考。
其一，PARP系列产品的迭代升级与联合治疗探索。塞纳帕利（PARP1/2抑制剂）作为公司当前的商业化基石，已为后续产品奠定了临床与市场基础。新一代PARP1抑制剂的核心价值，在于降低血液毒性、拓宽安全窗，从而更灵活地与ADC、化疗等联用，进一步拓展至乳腺癌、前列腺癌等患者基数更大的瘤种，以及PARP1/2抑制剂难以覆盖的适应症。
2026年，我们在美国临床肿瘤学会（ASCO）年会上公布了PARP1抑制剂IMP1734联合周疗紫杉醇治疗晚期实体瘤的1/2期临床数据。结果显示，该联合方案具可控的安全性特征，血液学毒性与周疗紫杉醇方案既往研究数据相近，证实了PARP1选择性抑制剂可与细胞毒性化疗安全联用，而且在接受过紫杉烷类药物治疗的患者中仍观察到令人鼓舞的抗肿瘤活性。此外，公司还在推进脑渗透型PARP1抑制剂IMP1707的临床研究，旨在探索脑转移和脑瘤这一更有挑战性的治疗领域。
其二，靶点协同规划，延长核心产品生命周期。ATR是合成致死领域的重要下一代靶点，我们将其定位为塞纳帕利的关键联用“伙伴”，尤其针对PARP抑制剂耐药的患者。目前，公司已启动“PARPi+ATRi”联合用药临床试验，旨在对DNA修复形成“双重打击”，从机制层面解决耐药问题，从而延长核心产品生命周期，并扩大其临床应用范围。
其三，持续探索前沿机制，布局下一代创新疗法。公司正积极布局PKMYT1/WEE1、DHX9、ATM、USP1、CHK1/2等新兴靶点，同时基于合成致死策略，拓展开发新型ADC和蛋白降解疗法。结合行业发展趋势并立足自身核心优势，英派已搭建了双载荷ADC与靶向蛋白降解两大技术平台，目前均已有候选药物分子处于临床前阶段，为未来持续输出差异化创新奠定基础。
药明康德：能否分享下英派药业在接下来1-2年，有哪些计划中的重要节点？
蔡遂雄博士：未来1-2年，是公司管线推进与全球化发展的关键窗口期。商业化方面，塞纳帕利的欧洲MAA申报有望于今年获批，届时将正式开启公司的国际商业化进程。在研管线方面，公司的多条合成致死管线将在今年下半年及此后1~2年陆续读出数据，为后续注册与适应症拓展提供支撑；与此同时，双载荷ADC与靶向蛋白降解等技术平台有望完成临床前验证，并启动IND申报，推动公司迈向多技术平台协同创新的新阶段。在全球布局方面，公司也将持续加大全球临床研发投入，并积极开展国际授权合作，以开放协同的方式提速整体研发进程。
药明康德：在创新药研发领域，您如何看待合作对于推动行业创新的积极作用？英派在多年前就开始与药明康德合作，能否分享下当时您和团队对药明康德的初印象？
蔡遂雄博士：在创新药研发的漫长过程中，没有任何一家企业能够独立完成所有环节。从靶点发现、分子研发生产，到最终药物上市，整个过程涉及数十个专业领域及多部门的高度协作，任何一环的短板都可能拖慢整体进程。因此，开放共赢的生态合作并非锦上添花，而是实现创新药成果落地的必经之路。
以英派药业与药明康德的合作为例，双方早在2012年便开启合作。当时我们团队最深的感受是，药明康德不仅拥有符合全球标准的质量体系，还具备快速响应的服务能力。这正是我们选择其作为长期合作伙伴的核心依据。具体而言，药明康德拥有小分子药物全链条研发平台；其实验室同步符合中美欧多地的质量合规标准；研发团队专业功底扎实、经验丰富；业内合作口碑稳定，且知识产权保护机制完善。这些优势与英派长期管线布局的发展诉求高度契合。
图片来源：123RF
药明康德：药明康德有幸参与了英派的塞纳帕利的研发过程。能否分享下塞纳帕利项目的合作故事？
蔡遂雄博士：与药明康德旗下合全药业的深度合作，始于塞纳帕利早期研发阶段。这款创新药承载着我们“让卵巢癌患者获得更好治疗选择”的重要使命，因此我们需要一个既深耕创新药研发、又具备高效执行能力的合作伙伴。合全药业团队在项目质量和时间保障方面表现非常优秀，陪伴塞纳帕利从实验室研究一步步走向临床、走向患者，让我们很省心，也很放心。
比如，在塞纳帕利的CMC开发过程中，合全药业基于平台优势和深厚技术储备，为项目提供了完善的原料药工艺开发与放大、处方前研究和制剂开发，确定了优质稳定的原料药和制剂工艺。这些扎实的早期工作，为后续的临床生产、新药注册和商业化奠定了坚实基础。
回顾多年合作历程，有一个时刻尤为值得分享。2025年1月，塞纳帕利正式获得中国NMPA批准上市。从获批到首方落地仅用了72小时。也就是说，新药获批与惠及患者几乎“无缝衔接”。创新药的NDA申报和商业化准备往往是并行推进的，这背后的时间窗极为紧张。英派药业及合全药业团队共同顶住了巨大压力，将两项工作并行推进。合全药业团队不仅按期协助我们完成了NDA申报资料的准备工作，还在获批后极短时间内完成商业化落地的各项衔接。感谢合全药业团队自始至终展现出的专业精神。
当然，这只是一个开始。塞纳帕利预计2026年下半年在欧洲获批。我们期待与合全药业继续保持紧密的合作关系，把塞纳帕利推进到国际市场，惠及更多患者，也给世界讲合作推进创新的故事。
药明康德：现阶段，“合成致死”新药研发领域面临的主要挑战是什么？展望未来5到10年，您认为该领域在疾病治疗方面有怎样的发展前景？
蔡遂雄博士：当前，合成致死领域面临的主要挑战在于，已验证的有效靶点少，生物学机制研究与创新靶点挖掘是核心瓶颈。这也是英派现阶段重点深耕的两大方向。随着各类创新技术的发展，未来靶点发现效率有望提升，也有望为疾病治疗带来更多突破。
展望未来5-10年，我认为合成致死有望进入多靶点、联合治疗和新技术协同发展的新阶段。在适应症方面有望持续扩容，覆盖各类DDR缺陷实体瘤；其中，具备高透脑能力的分子也有望在脑瘤治疗领域发挥重要作用。在治疗策略上，合成致死可与化疗、ADC、RDC等多种手段联用，通过强协同作用，为患者提供更加多样化、个体化的联合方案。此外，该领域有望突破传统小分子的局限，拓展至蛋白降解疗法、双载荷ADC等更多新型疗法。
而英派，正是这一趋势的践行者。从塞纳帕利的商业化落地，到PARP1、ATR等管线的纵深布局，再到双载荷ADC与蛋白降解平台的前沿探索，英派始终以“合成致死”为锚点，持续构建差异化的创新管线。我们相信，扎根科学、开放合作、坚持长期主义，是让创新成果真正转化为患者获益的关键路径——这也是英派始终不变的初心与方向。
Behind the Milestone: IMPACT Therapeutics’ Journey from Lab to Life and Focus for the Future | An Interview with Dr. Sui Xiong Cai
In 2009, when IMPACT Therapeutics entered the field of synthetic lethality, no PARP inhibitor had yet been approved anywhere in the world. The scientific and commercial outlook remained uncertain at that time, and the risks were considerable. Yet, IMPACT chose to pursue that opportunity with more than a decade of persistent effort.
In January 2025, senaparib—IMPACT’s internally developed PARP inhibitor—was approved in China. Later that year, it was included in China’s National Reimbursement Drug List (NRDL). Separately, the company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). On May 13, 2026, IMPACT was listed on the Main Board of the Hong Kong Stock Exchange. At the end of July, IMPACT entered into an exclusive partnership with Pharmanovia, a global specialty pharmaceutical company, to grant Pharmanovia the exclusive rights to manufacture, develop and commercialise senaparib in Europe, Middle East and North Africa, Australia and New Zealand for maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer. The partnership represents an important step in bringing senaparib to global patients.
From 2009 to 2026, the company progressed from early-stage research and development to commercialization, and ultimately, the public markets.
“Listing is only the beginning of a new chapter for the company. Our ultimate goal is to bring more differentiated, innovative, and effective therapies to patients with solid tumors worldwide,” Dr. Sui Xiong Cai, Chief Executive Officer of IMPACT Therapeutics, said in a recent interview with WuXi AppTec.
Dr. Cai joined IMPACT at its founding and has witnessed the company’s journey from its earliest days.
In his view, the company’s ability to sustain itself through a long development cycle reflects both the team’s conviction in its scientific strategy and the support of a broader collaborative ecosystem. During the interview, he highlighted the long-standing trust of investors, the continuous support of CRDMO partner WuXi AppTec, and the close collaboration with numerous partners.
“On the long road of innovative drug development, no company can succeed alone,” Dr. Cai said. “Open, mutually beneficial collaboration across the ecosystem is not simply a nice-to-have—it is essential to turning innovative science into new medicines.”
After 17 years of sustained effort, IMPACT has navigated the full drug development journey, from laboratory research to delivering a therapy to patients. Each milestone has also strengthened the company’s confidence and capabilities as it enters its next phase of innovation.
The following conversation with Dr. Sui Xiong Cai has been edited for clarity and length.
WuXi AppTec: Congratulations on IMPACT’s successful IPO. Having been closely involved in the company’s growth, what personal reflections do you have on reaching this milestone?
Dr. Sui Xiong Cai: IMPACT Therapeutics listed on the Main Board of the Hong Kong Stock Exchange on May 13, 2026. It was a significant milestone for both the company and the broader industry. I feel privileged to have witnessed IMPACT’s entire 17-year journey since its founding in 2009—a journey defined by perseverance and long-term commitment. When we set our company’s overall strategy as “rooted in China, with a global vision,” aiming to develop best-in-class (BIC) novel drugs, and anchored our focus on the synthetic lethality approach, no PARP inhibitor had yet been approved anywhere in the world. Both the clinical development pathway and the commercial potential of the field remained highly uncertain. After more than a decade of sustained effort, we successfully developed and launched our lead product, senaparib. Building on that foundation, we have established a broader and more systematic pipeline focused on synthetic lethality.
But we have not stopped there. To address a wider range of therapeutic needs, we have continued to expand the boundaries of our innovation by establishing two proprietary technology platforms: a dual-payload antibody-drug conjugate (ADC) platform and a proteolysis-targeting chimera platform.
The listing marks the beginning of IMPACT’s next stage of growth. Our ultimate goal remains unchanged: to bring more differentiated, innovative, and effective therapies to patients with solid tumors worldwide.
WuXi AppTec: Looking back on senaparib’s development, what were the biggest challenges, and what lessons did you take from the experience?
Dr. Sui Xiong Cai: Senaparib is IMPACT’s internally discovered and developed PARP inhibitor. We identified the candidate in 2012, secured approval in China in 2025, and saw it included in the NRDL later that year, making it a more accessible treatment option for patients with ovarian cancer. Also in 2025, the EMA accepted the drug’s marketing authorization application for review. Our recent partnership with Pharmanovia marks a significant step for IMPACT to bring its validated treatment options to more patients worldwide. We expect senaparib to reach target patients in the collaboration territories more quickly following approval, helping to deliver high-quality treatment options to address unmet medical needs.
Looking back, we faced two major challenges.
The first was balancing strategic focus with limited resources. At that time, the outlook for PARP inhibitors remained uncertain, while IMPACT had a very small team and highly constrained R&D resources. Our ability to grow from a single laboratory into a company with a commercial product and a public listing owes a great deal to our core R&D team, who have remained on the front lines throughout the journey, our commitment to developing new drugs against the best-in-class standard, and the long-term trust and support of our investors. What sustained us through those years was the conviction that we had to remain committed to what we believed was scientifically sound, even amid considerable uncertainty.
The second challenge involved several critical decisions about the clinical development strategy. In 2019, based on our deep understanding of the synthetic lethality mechanism and strong Phase 1 data, we decided to move directly into the Phase 3 FLAMES study without conducting a separate Phase 2 trial. That decision shortened the development timeline by more than two years. More importantly, we chose a more challenging path that we believed could deliver greater clinical value: evaluating senaparib as a first-line maintenance therapy in an all-comer population, rather than limiting enrollment to patients with BRCA or HRR mutations. Ultimately, supported by a comprehensive body of clinical evidence, we secured approval for first-line maintenance treatment across the broader ovarian cancer population.
Image source: 123RF
This journey reinforced our belief that sound scientific judgment and strategic trade-offs are often more important than simply increasing investment. When resources are limited, the ability to interpret clinical data accurately and act decisively can be critical to overcoming development bottlenecks. It also confirmed that drug development is never a solo endeavor. Few companies can independently manage every stage of the process, and industry collaboration can play an important role in reducing risk and accelerating progress. Across the research, development, and manufacturing of senaparib, WuXi AppTec’s platform capabilities helped us shorten timelines and reduce the cost of trial and error. In many ways, that experience illustrates how effective partnerships can accelerate innovation.
WuXi AppTec: Beyond senaparib, how is IMPACT Therapeutics approaching pipeline development and target selection in the field of synthetic lethality?
Dr. Sui Xiong Cai: Our pipeline strategy is built around three priorities: advancing successive generations of products, developing complementary combinations, and exploring emerging mechanisms.
First, we are continuing to advance our PARP inhibitor portfolio while exploring new combination strategies. Senaparib, a PARP1/2 inhibitor, is currently the commercial foundation of our portfolio and has established a strong clinical and market base for the development of follow-on products. The potential value of a next-generation PARP1-selective inhibitor lies in reducing hematological toxicity and widening the therapeutic window. This could enable more flexible combinations with ADCs, chemotherapy, and other treatment modalities. It could also support expansion into larger indications, including breast and prostate cancers, as well as tumor types that may be more difficult to address with PARP1/2 inhibitors.
At the 2026 ASCO Annual Meeting, we presented Phase 1/2 clinical data evaluating the PARP1 inhibitor IMP1734 in combination with weekly paclitaxel in patients with advanced solid tumors. The combination demonstrated a manageable safety profile, with hematologic toxicity comparable to historical data for weekly paclitaxel alone. These findings support the potential for a PARP1-selective inhibitor to be safely combined with cytotoxic chemotherapy. Encouraging antitumor activity was also observed in patients who had previously received taxane-based treatment.
We are also advancing clinical development of IMP1707, a brain-penetrant PARP1 inhibitor designed to address more challenging settings, including brain metastases and primary brain tumors.
Second, we are pursuing complementary targets that could extend the clinical utility and lifecycle of our core products. ATR is an important next-generation target in synthetic lethality, and we view it as a potentially valuable combination partner for senaparib, particularly in patients who develop resistance to PARP inhibitors. We have initiated clinical trials evaluating the combination of a PARP inhibitor and an ATR inhibitor. The goal is to deliver a “double hit” to the DNA damage response pathway, address resistance at the mechanistic level, and potentially broaden the clinical use of senaparib.
Third, we are continuing to explore novel mechanisms and develop next-generation therapeutic approaches. Our research includes emerging targets such as PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2. At the same time, we are extending our synthetic lethality strategy into emerging modalities, including next-generation ADCs and targeted protein degraders. Building on industry trends and our core scientific capabilities, IMPACT has established two proprietary technology platforms: a dual-payload ADC platform and a targeted protein degradation platform. Both platforms currently include preclinical-stage candidates and provide a foundation for differentiated innovation in the future.
WuXi AppTec: What key milestones does IMPACT Therapeutics expect to reach over the next one to two years?
Dr. Sui Xiong Cai: The next one to two years will be a critical period for advancing our pipeline and global development strategy.
On the commercial front, we expect a decision on the European marketing authorization application for senaparib this year. A potential approval would mark an important step in the company’s international commercialization journey.
Across the pipeline, several of our synthetic lethality programs are expected to generate clinical data in the second half of this year and over the following one to two years. These readouts could support future regulatory filings and the expansion of our products into additional indications.
At the same time, we expect our dual-payload ADC and targeted protein degradation platforms to complete key preclinical validation work and begin advancing candidates toward IND submissions. This would move IMPACT into a new phase of innovation built around multiple complementary technology platforms.
We also plan to increase our investment in global clinical development and actively pursue international licensing partnerships. Through an open and collaborative approach, we aim to accelerate development and bring our therapies to patients in more markets.
WuXi AppTec: How do you see collaboration contributing to innovation in drug development? When IMPACT first began working with WuXi AppTec, what stood out to your team?
Dr. Sui Xiong Cai: No company can independently manage every stage of the long and complex drug development process. From target discovery and molecule development to manufacturing and regulatory approval, progress depends on close coordination across dozens of specialized disciplines and multiple functions. A gap at any point can delay the entire program. That is why open, mutually beneficial collaboration across the broader ecosystem is more than a catchphrase. It is essential to successfully translate innovative science into new medicines.
Take the partnership between IMPACT and WuXi AppTec as an example. The collaboration began as early as 2012. What initially stood out to our team was the combination of a globally aligned quality system and the ability to respond quickly. Those capabilities were central to our decision to select WuXi AppTec as a long-term partner.
More specifically, WuXi AppTec offers an integrated small-molecule CRDMO platform, laboratories that operate in accordance with regulatory standards in China, the United States, and Europe, and experienced scientific teams with strong technical expertise. The company also has a solid reputation for collaboration across the industry and well-established intellectual property protection mechanisms. These strengths are closely aligned with the needs of IMPACT’s long-term pipeline strategy.
Image source: 123RF
WuXi AppTec: Could you share the story behind our collaboration on the senaparib program?
Dr. Sui Xiong Cai: Our partnership with WuXi STA began during the early stages of senaparib’s development. The program was driven by an important goal: to provide patients with ovarian cancer with better treatment options. We therefore needed a partner with both deep experience in innovative drug development and the ability to execute efficiently. The WuXi STA team consistently delivered on both quality and timelines. They supported senaparib throughout its journey—from laboratory research and clinical supply to commercialization and, ultimately, reaching patients. That gave us considerable confidence and peace of mind.
During senaparib’s CMC development, for example, the WuXi STA team provided a broad range of services, including API process development and scale-up, preformulation development, and formulation development. Together, these efforts resulted in a robust, stable, and high-quality API and formulation process. This early work laid a strong foundation for subsequent clinical manufacturing, NDA registration, and commercialization.
Looking back on our years of collaboration, one moment stands out in particular. Senaparib received marketing approval from China’s National Medical Products Administration (NMPA) in January 2025, and the first prescription was filled just 72 hours later. The transition from regulatory approval to patient access was nearly seamless.
For an innovative drug, preparations for an NDA submission and commercial launch often needs to proceed in parallel, creating an extremely demanding timeline. The IMPACT and WuXi STA teams worked under significant pressure to advance both workstreams simultaneously. WuXi STA supported us in completing the NDA submission package on schedule and, just as importantly, helped ensure that commercial launch preparations were in place within the very short window following approval. We are grateful to the team for the professionalism and commitment they demonstrated throughout the process.
Of course, this is only the beginning. Senaparib is expected to receive a regulatory decision in Europe in the second half of 2026. We look forward to continuing our close partnership with WuXi STA as we work to bring senaparib to international markets, reach more patients, and advance the next phase of our collaboration.
WuXi AppTec: What are the main challenges facing synthetic lethality research and development today? Looking ahead five to ten years, how do you see the field evolving in the treatment of disease?
Dr. Sui Xiong Cai: The main challenge in synthetic lethality today is the limited number of clinically validated targets. The key bottlenecks are gaining a deeper understanding of the underlying biology and identifying new targets. These are also two of the areas on which IMPACT is currently most focused. As new technologies continue to advance, we expect target discovery to become more efficient, potentially opening the door to further breakthroughs in disease treatment.
Looking ahead five to ten years, I believe synthetic lethality will enter a new phase characterized by multi-target strategies, combination therapies, and the synergistic integration of emerging technologies. From an indication perspective, the field could expand across a broader range of solid tumors with DNA damage response deficiencies. Molecules with strong brain penetration may also play an important role in the treatment of primary brain tumors and brain metastases. From a therapeutic strategy perspective, synthetic lethality could be combined with a range of modalities, including chemotherapy, ADCs, and radiopharmaceutical drug conjugates (RDCs). These combinations may generate meaningful synergistic effects and provide patients with more diverse and personalized treatment options. The field is also likely to move beyond traditional small molecules and expand into newer therapeutic approaches, including targeted protein degradation and dual-payload ADCs.
IMPACT Therapeutics reflects this broader evolution. We began with the development and commercialization of senaparib, then expanded more deeply into programs targeting PARP1 and ATR, and are now exploring dual-payload ADC and targeted protein degradation platforms. Throughout this progression, we have remained firmly focused on synthetic lethality while continuing to build a differentiated pipeline.
We believe that staying grounded in science, embracing open collaboration, and maintaining a long-term perspective are essential to translating innovation into meaningful benefits for patients. That remains at the core of IMPACT’s mission.
免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。
版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。
分享，点赞，在看，聚焦全球生物医药健康创新
